PMN:TSX; ARFXF:OTCQB

ProMIS Neurosciences Inc.

ProMIS Neurosciences is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s disease, the DSE’s are misfolded regions on otherwise normal proteins. In the infectious disease setting, these disease-specific epitopes represent peptide antigens that can be used as an essential component to create accurate and sensitive serological assays to detect the presence of antibodies that arise in response to a specific infection, such as COVID-19.
PMN:TSX ARFXF:OTCQB
View Company News
Visit Company Website

Expert Comments:

Neurosciences Firm Provides Insight on Recent Alzheimer's/Amyloid Field Developments
(2/3/21)

ProMIS Neurosciences offered its perspective on the latest progress in the Alzheimer's/Amyloid field. The firm stated that two recent positive events support the case for PMN310 to be considered "best in class."
read more >

Neurosciences Firm Outlines Strategic Priorities for 2021
(1/15/21)

ProMIS Neurosciences discusses its four priority areas in 2021.
read more >

Biotech Involved in COVID-19, Neurodegenerative Diseases Reports Q3/20 Results
(11/12/20)

ProMIS Neurosciences formed two new joint ventures, one for developing tests for the detection, diagnosis and monitoring of Alzheimer's disease, and the second for serological assays for antibodies to the SARS-CoV-2 virus.
read more >

Biotech Comments on FDA Advisory Committee Recommendation of Not Licensing Alzheimer's Drug
(11/11/20)

ProMIS Neurosciences, which is developing its own therapeutics for this disease, weighs in on the committee's conclusions regarding Biogen's aducanumab.
read more >

Biopharma White Paper Posits FDA Approval of Biogen's Alzheimer's Drug Likely Next Month
(10/23/20)

ProMIS Neurosciences cites "unequivocally positive data" and encouraging FDA actions with respect to the therapeutic.
read more >

Clive Maund, CliveMaund.com

(7/14/20)
"This is a good point for ProMIS Neurosciences Inc.'s stock to start advancing again. . .the reason for us taking an interest in it here is that, given the proximity of support, we can place a fairly close stop to take us out if the support fails, which means that we have a favorable risk/reward ratio because the upside is relatively unlimited. The company is therefore rated an Immediate Buy here."

Cosme Ordonez, Noble Capital Markets

(4/20/20)
"ProMIS Neurosciences Inc. announced a collaboration to develop a sensitive and specific laboratory test to detect antibodies against SARS-CoV-2, the virus causing Covid-19. Given ProMIS' experience with peptide and antibody based technologies, we believe the company and its collaborators will be able to develop a specific test without cross-reactivity with other viruses in the coronavirus family. Thus far, high test specificity has been a challenge for the industry. . . In our opinion, ProMIS could potentially attract a big pharmaceutical company to sign a partnership to advance development of vectorization technology."

More Expert Comments

Experts Following This Company

Clive Maund – CliveMaund.com
John Vandermosten, CFA – Zacks Small-Cap Research

Company News

3/31/2021 – ProMIS Neurosciences Announces Fiscal Year 2020 Results

3/22/2021 – ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors

2/2/2021 – ProMIS Neurosciences Offers Perspectives on Recent Progress in the Alzheimer's/Amyloid Field

The information provided above is from analysts, newsletters, the company and other contributors.

ProMIS Neurosciences Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
 Unique tech. platform creates highly selective antibodies for root cause of Alzheimer’s, ALS and Parkinson’s
 
 2nd generation PMN 310, anticipated to show significant advantages in efficacy & safety vs Biogen’s 1st to market aducanumab in Alzheimer’s
 
 Unique platform supports development of highly sensitive & specific blood test for antibodies specific for COVID-19
catalyst Calendar
Q2
2020
Potential successful serological antibody test for COVID-19 (end June 2020); expansion of current co
Q2
2020
Potential collaborations with pharma partners/patient associations forALS, Parkinson’s disease (comi
Q3
2020
Anticipated approval of Biogen’s aducanumab for AD, rolling BLA ongoing, news expected around end Q3
ProMIS Neurosciences Inc. Content
go
Corporate Presentation November 2020